3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Phase 2
1
Phase 1/2
1
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Carcinoma, Transitional Cell
7
Urinary Bladder Neoplasms
4
Ureteral Neoplasms
2
Urologic Neoplasms
1
Urethral Neoplasms
1
Peripheral Nervous System Diseases
1
Non-Muscle Invasive Bladder Neoplasms
1
Neoplasms
1
Neoplasm Metastasis
1
Metastatic Urothelial Cancer and Other Malignant Solid Tumors
1
Carcinoma in Situ
1
Interventions
pembrolizumab
3
atezolizumab
2
testosterone 17 beta-cypionate
1
temsirolimus
1
poly ICLC
1
lenvatinib
1
enfortumab vedotin
1
Valproic Acid
1
Testosterone Propionate
1
Sunitinib
1
Standard of Care
1
Sirolimus
1
Saline Solution
1
Prednisone
1
Practice Guidelines as Topic
1
Methyltestosterone
1
Immunoglobulin G
1
Gemcitabine
1
GSK-3326595
1
Etoposide
1
Doxycycline
1
Docetaxel
1
Disulfides
1
Cyclophosphamide
1
Cetuximab
1
Capecitabine
1
Bevacizumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Urologic Neoplasms
×
enfortumab vedotin
×
Clear all
NCT05614739
2026-05-19
FORAGER-1
Eli Lilly and Company
Phase 1
Recruiting
535 enrolled